Orange: Minimal data to guide interaction

Label

Potential interactions

Color

Orange

Icon

Alert Outline

Displaying 101 - 200 of 280

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Atazanavir Midazolam 861	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased midazolam effects (eg, increased sedation, confusion, respiratory depression)				Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.
Atazanavir Quinidine 860	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased quinidine effects (e.g. cardiac arrhythmias)				If coadministering use with caution. Monitor for toxicity.
Atazanavir Propafenone 859	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased propafenone effects (eg, cardiac arrhythmias)				If coadministering use with caution. Monitor for toxicity.
Atazanavir Amiodarone 858	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)				If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
Atazanavir Lidocaine 857	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering use with caution. Monitor adverse effects and consider therapeutic drug monitoring.
Atazanavir Flecainide 856	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)				If coadministering use with caution and monitor for toxicity. Consider therapeutic drug monitoring
Atazanavir Mexiletine 855	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of mexiletine adverse effects				If coadministering use with caution and monitor for mexiletine toxicity
Atazanavir Disopyramide 854	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of disopyramide adverse effects				If coadministering use with caution and monitor for disopyramide toxicity
Atazanavir Proguanil 853	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially compromised antimalarial activity	Not reported	100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 41%, Cmax no significant change	If coadministering monitor for anti-malarial efficacy
Atazanavir Digoxin 852	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of digoxin toxicity				If coadministering digoxin dose may need to be decreased. Monitor digoxin level and adjust digoxin dose based on clinical signs and drug levels.
Atazanavir Atovaquone 851	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential compromised antimalarial activity	Not reported	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 46%, Cmax decreased 49%	Dose adjustment not established. If coadministering monitor for anti-malarial efficacy.
Atazanavir Telithromycin 850	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased telithromycin effects. (e.g. may cause QTc prolongation)				Avoid combination or use alternative agents
Atazanavir Vorapaxar 849	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Use alternative agents
Atazanavir Ticagrelor 848	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Use alternative agents
Atazanavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 847	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Do not coadminister
Atazanavir Clarithromycin 846	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Consider alternative antibiotics
Atazanavir Phenobarbital 845	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiretroviral efficacy				Avoid combination or use alternative agents
Atazanavir Phenytoin 844	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiretroviral efficacy				Avoid combination or use alternative agents
Atazanavir Apixaban 843	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Avoid combination, use alternative anticoagulant
Atazanavir Erythromycin 842	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Avoid combination, use alternative antibiotics
Tenofovir disoproxil fumarate LDV/SOF 753	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of TDF adverse effects (e.g. renal function decline)	AUC increase 40%-98%, Cmin increase 55-80% when TDF coadministered with rilpivirine and efavirenz or various PIs, INSTIs, and NNRTIs	90 / 400 mg once daily	Not studied	If coadministering, monitor for TDF adverse effects. Avoid use if CrCl >60 ml / min.
Tenofovir disoproxil fumarate DRV 752	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of TDF and / or darunavir adverse effects	Cmax increase 24%, AUC increase 22%, Cmin increase 37%	300 mg BID with ritonavir 100 mg BID	Cmax increase 16%, AUC increase 21%, Cmin increase 24%	If coadministering, monitor for TDF adverse effects (e.g. renal function decline)
Tenofovir disoproxil fumarate SOF/VEL/VOX 751	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Increase AUC 30-80% when given with various ARV containing TDF		Not studied	If coadministering, monitor for TDF adverse effects
Tenofovir disoproxil fumarate SOF/VEL 750	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Cmax increased 36%; AUC increased 35%; Cmin increased 45%	400 / 100mg once daily	Not studied	If coadministering, monitor for TDF adverse effects
Tenofovir disoproxil fumarate Valganciclovir 749	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of TDF and / or ganciclovir adverse effects	Not studied (may increase TDF levels)		Not studied (may increase ganciclovir levels)	If coadministering, monitor for adverse effects
Tenofovir disoproxil fumarate Ganciclovir 748	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of TDF and / or ganciclovir adverse effects	Not studied (may increase TDF levels)		Not studied (may increase ganciclovir levels)	If coadministering, monitor for adverse effects
Lamivudine Sorbitol 701	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potentially decreased lamivudine efficacy	AUC decreased 20-44%	3.2 - 13.4 grams daily	Not studied	Consider using alternative agents. Interaction studied with liquid formulation. If unable to avoid co-administration, monitor for virologic efficacy.
Nevirapine CsA 642	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Nevirapine Clarithromycin 641	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	Decreased clarithromycin effects but increased metabolite concentrations		500 mg BID	Clarithromycin AUC decreased 31%; Cmax decreased 23%; Cmin decreased 56%; 14-hydroxy clarithromycin AUC increased 42%, Cmax increased 47%	Consider using alternative agents such as Azithromycin
Nevirapine MMF, MPA 640	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination		No significant change	500 mg BID x 8 weeks	Not studied	Use alternative agents
Nevirapine DRV 639	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased Nevirapine effects, increased risk of hepatotoxcity	AUC increased 110%			Use alternative agents
Nevirapine SQV 638	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased saquinavir effects	Not studied	600 mg (hard gel caps) TID	Saquinavir AUC decreased 24%; Cmax decreased 28%	Use alternative agents
Nevirapine Diltiazem 637	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased dilitazem efficacy				If coadministring, titrate dilitazem based on clinical response
Nevirapine CBZ 636	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased anticonvulsant and NVP concentration				If coadministring, monitor anticonvulsant and NVP concentration
Nevirapine Caffeine / Ergotamine 635	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Ergotamine levels may be decreased	No significant change		Not studied (may decrease ergot levels)	If coadministering, monitor for ergot efficacy
Nevirapine Warfarin 634	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased warfarin effects (eg, altered INR, increased risk of clotting)				If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Nevirapine Bosentan 633	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased etravirine effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Nevirapine Ticagrelor 632	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Nevirapine Itraconazole 631	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects and possible NVP concentrati			Itraconazole AUC decreased 61%	Avoid combination and use alternative agents
Nevirapine Tamsulosin 630	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	Decreased tamsulosin effects				If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
Etravirine Verapamil 573	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased verampil efficacy				If coadministring, titrate verapamil based on clinical response
Etravirine Diltiazem 572	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased dilitazem efficacy				If coadministring, titrate dilitazem based on clinical response
Etravirine Warfarin 571	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased Warfarin concentration				If coadministring, monitor INR
Etravirine Trazodone 570	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiential decreaed Trazodone effects				If coadministring, monitor for theraptutic effectiveness of Trazodone
Etravirine Sertraline 569	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiential decreaed Sertaline effects				If coadministring, monitor for theraptutic effectiveness of Sertaline
Etravirine Zonisamide 568	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Tiagabine 567	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Lacosamide 566	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Ethosuximide 565	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Lumefantrine 564	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased antimalarial effects	No significant change	artemether / Lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 13%	If coadministering, monitor for anti-malarial efficacy.
Etravirine Itraconazole 563	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased itraconazole effects	Not studied (may increase etravirine levels)		Not studied (may decrease itraconazole levels)	If coadministering, dose adjustment not established. Monitor itraconazole levels and etravirine toxicity.
Etravirine Artemether / Lumefantrine 562	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased antimalarial effects	No significant change	artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 38%; Lumefantrine AUC decreased 13%	Use with caution; avoid if possible
Etravirine Clarithromycin 561	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased etravirine effects; decreased clarithromycin effects	Etravirine AUC increased 42%; Cmax increased 46%; Cmin increased 46%	500 mg BID	Clarithromycin AUC decreased 37%; Cmax decreased 34%; Cmin decreased 53%; 14-hydroxyclarithromycin AUC increased 21%; Cmax increased 33%	Use alternative macrolide (consider use of azithromycin) for MAC
Etravirine Bosentan 560	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased etravirine effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Etravirine Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 559	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potentially decreased or increased elvitegravir, cobicistat and / or etravirine effects	No significant change	Elvitegravir 150 mg daily	No significant change	Avoid combination and use alternative agents
Etravirine Clopidogrel 558	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased clopidogrel effects				Avoid combination and use alternative agents
Etravirine Tamsulosin 557	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	Decreased tamsulosin effects				If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
Efavirenz CBZ 512	Orange: Minimal data to guide interaction		Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease carbamazepine levels)	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Tacrolimus 511	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz Sirolimus 510	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 509	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 508	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 507	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CBZ 506	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	EFV auc decreased 36%, Cmax decreased 21%, Cmin decreased 47%	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 15 days		Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz CBZ 505	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin decreased 35%, Cmax decreased 20%	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz CBZ 504	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin 35%, Cmax decreased 20%	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Midazolam 503	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Not studied (may increase midazolam levels)	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.
Efavirenz NVP 502	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz effects	Efavirenz AUC decreased 22%; Cmin decreased 36%	200 mg daily x 2 weeks, then 400 mg daily	No significant change	Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg daily
Efavirenz Warfarin 501	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Warfarin 500	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Warfarin 499	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Clarithromycin 498	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Clarithromycin 497	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Clarithromycin 496	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Bosentan 495	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased Efavirenz effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Efavirenz Proguanil 494	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits			100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 43%; Cmax no significant change	Consider using alternative agents. If coadministering, dose adjustment not established
Efavirenz Proguanil 493	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased antimalarial effects		300 mg x 1	Proguanil AUC increased 113%; Cmax increased 47%; Cycloguanil AUC decreased 38%; Cmax decreased 31%	Consider using alternative agents. If coadministering, dose adjustment not established
Efavirenz Posaconazole 492	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects		400 mg BID x 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Posaconazole 491	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects	No significant change	400 mg BID for 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Posaconazole 490	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects	No significant change	400 mg BID	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Phenobarbital 489	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects			Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenobarbital 488	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects	Not studied (may decrease levels)		Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenobarbital 487	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects	Not studied (may decrease levels)		Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenytoin 486	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz and phenytoin effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease phenytoin levels)	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
Efavirenz Phenytoin 485	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz and phenytoin effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease phenytoin levels)	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
Efavirenz Ticagrelor 484	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Efavirenz Clopidogrel 483	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased activation of clopidogrel				Avoid combination and use alternative agents
Efavirenz Triazolam 482	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased triazolam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Not studied (may increase triazolam levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 481	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects			Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 480	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects	Not studied		Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 479	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects	Not studied		Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Itraconazole 478	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects		200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Itraconazole 477	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects		200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Itraconazole 476	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects	No significant change	200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Atovaquone 475	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Atovaquone 474	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Atovaquone 473	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 472	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 79%, Lumefantrine AUC decreased 30%-56%.	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 471	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity	EFV AUC decreased 17%	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%.	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 470	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.

Subscribe to Orange: Minimal data to guide interaction